Investigational drug · Phase 2
RSLV-132
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Sjögren Syndrome.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "RSLV-132"
First trial start
2024
Dec 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RSLV-132", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Sjögren Syndrome
Approved drugs for the same conditions: Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "RSLV-132" as an intervention, largest first.
- Phase 2 Study of RSLV-132 in Subjects With Long COVIDPivotal-lookingCompleted
Resolve TherapeuticsIndustry
NCT04944121 · 112 participants · Start Jun 25, 2021 · Primary completion Oct 31, 2023
Drug: RSLV-132; Sodium Chloride 0.9% · For: Post-acute Corona Virus 19 (COVID-19) (Long COVID)
Sites: Mobile, Alabama; Coral Gables, Florida; Pompano Beach, Florida · 5 sites in all
- A Study of RSLV-132 in Females With Sjögren's DiseasePivotal-lookingActive, not recruiting
Resolve TherapeuticsIndustry
NCT06440525 · 106 participants (planned) · Start Dec 1, 2024 · Primary completion May 1, 2027
Drug: RSLV-132; Placebo · For: Primary Sjögren Syndrome
Sites: Chula Vista, California; Tustin, California; Boca Raton, Florida · 24 sites in all
Resolve TherapeuticsIndustry
NCT02660944 · 64 participants · Start Jan 3, 2016 · Primary completion May 28, 2020
Drug: RSLV-132; Placebo · For: Systemic Lupus Erythematosus
Sites: El Cajon, California; La Jolla, California; Los Alamitos, California · 16 sites in all
Resolve TherapeuticsIndustry
NCT02194400 · 32 participants · Start Jul 2014 · Primary completion Nov 2015
Drug: RSLV-132 · For: Systemic Lupus Erythematosus
Sites: Clearwater, Florida; Grand Rapids, Michigan; Duncansville, Pennsylvania · 4 sites in all
Resolve TherapeuticsIndustry
NCT03247686 · 28 participants · Start Feb 1, 2017 · Primary completion Jul 15, 2018
Drug: RSLV-132; Placebo · For: Sjogren's Syndrome
Sites: Birmingham, United Kingdom; Newcastle upon Tyne, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.
Xia L, Wang Y, Yan X, et al. · Mol Biomed 2026
- Targeted therapies against type I interferon and TNF-alpha in cutaneous lupus erythematosus: A systematic review of randomized trials.
Candia González DA, Dávila Vargas D, Arango Machado V, et al. · Dermatol Online J 2026
- Efficacy and safety of emerging immunomodulatory agents versus standard therapies in refractory cutaneous lupus: A systematic review.
Gómez Ballesta FJ, Paternina Álvarez MC, Betancourt Benítez AI, et al. · Dermatol Online J 2026
- Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection: A Randomized Phase 2 Trial of RSLV-132.
Andrews JS, Boonyaratanakornkit JB, Krusinska E, et al. · Clin Infect Dis 2024
- Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Burge DJ, Werth VP, Boackle SA, et al. · Lupus Sci Med 2024
- Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
Posada J, Valadkhan S, Burge D, et al. · Arthritis Rheumatol 2021
Also in development for Primary Sjögren Syndrome
- ESG206ESG206-2Phase 23 trials
Shanghai Escugen Biotechnology Co., Ltd · Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.